Cargando…

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?

Novel drugs have improved survival for patients with multiple myeloma in recent years. However, the disease is still fatal. Allogeneic stem cell transplantation (Allo) has proven to cure some patients with the disease, but its role is controversial due to relatively high transplant-related toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gahrton, Gösta, Iacobelli, Simona, Garderet, Laurent, Yakoub-Agha, Ibrahim, Schönland, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408931/ https://www.ncbi.nlm.nih.gov/pubmed/32664274 http://dx.doi.org/10.3390/jcm9072180

Ejemplares similares

Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
por: Auner, Holger W., et al.
Publicado: (2018)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
por: Lawless, Sarah, et al.
Publicado: (2022)

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
por: Hayden, Patrick J., et al.
Publicado: (2021)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
por: Park, Hyunkyung, et al.
Publicado: (2020)

Does thrombo-aspiration still have a place in the treatment of myocardial infarction?
por: Schiele, François, et al.
Publicado: (2016)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

Commentary: Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis
por: Beauvais, David, et al.
Publicado: (2022)

Hydroxychloroquine in Covid-19: Does the end justify the means?
por: Yakoub-Agha, Ibrahim
Publicado: (2020)

Does fine-needle aspiration biopsy still have a place in the diagnosis of breast lesions?
por: Obrzut, Marzanna, et al.
Publicado: (2018)

Does conventional laser photocoagulation still have a place in the treatment of diabetic macular edema?
por: Kayhan, Belma, et al.
Publicado: (2021)

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation
por: Mosebach, Jennifer, et al.
Publicado: (2018)

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
por: Waszczuk-Gajda, Anna, et al.
Publicado: (2022)

Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?
por: Martino, Massimo, et al.
Publicado: (2023)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Do Corticosteroids Still Have a Place in the Treatment of Chronic Pain?
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2018)

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Beauvais, D., et al.
Publicado: (2022)

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
por: Greinix, Hildegard T., et al.
Publicado: (2021)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation
por: Vantyghem, Marie-Christine, et al.
Publicado: (2014)

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
por: Drozd-Sokołowska, Joanna, et al.
Publicado: (2022)

Private Practice—Does It Have a Place?
por: Bailey, Ian S.
Publicado: (1991)

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
por: Penack, Olaf, et al.
Publicado: (2021)

Is there still a place for thrombectomy?
por: Dąbrowski, Maciej, et al.
Publicado: (2016)

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
por: Goldschmidt, Hartmut, et al.
Publicado: (2018)

Role of Allogeneic Transplantation in Multiple Myeloma in the Era of New Drugs
por: Bruno, Benedetto, et al.
Publicado: (2010)

Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience
por: Diarra, Ava, et al.
Publicado: (2022)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Does alternative therapy have a place in the RBO?
por: Camanho, Gilberto Luis
Publicado: (2013)

Does shaming have a place in public health?
por: Duong, Diana
Publicado: (2021)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?
por: Poussard, Margaux, et al.
Publicado: (2022)

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
por: Vincent, L, et al.
Publicado: (2015)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023)

A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation
por: Hudspeth, Michelle, et al.
Publicado: (2022)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8r5pp96iei03bd8cspsd58idam